News Release

It's all about the timing: Fetal expression of core clock gene determines lifespan in mice

Penn study prompts reevaluation of assumptions on role of internal clock in human disease

Peer-Reviewed Publication

University of Pennsylvania School of Medicine

Molecular Clock

image: Is the molecular clock essential to retard aging? view more 

Credit: Guangrui Yang PhD, Perelman School of Medicine, University of Pennsylvania

PHILADELPHIA - Abolishing the 24-hour clock by knocking out a key gene during development accelerates aging and shortens lifespan by two thirds in mice, but this effect is absent if the gene deletion is delayed until after birth, according to a new study published this week in Science Translational Medicine by scientists from the Perelman School of Medicine at the University of Pennsylvania.

As humans age, biological rhythms flatten, slow down, and eventually stop. Whether this relationship between aging and the molecular clock that drives such rhythms reflects cause or effect is unknown. To assess the role of the molecular clock in aging, Penn researchers, led by senior author Garret A. FitzGerald MD, chair of the department of Systems Pharmacology and Translational Therapeutics, made conditional Bmal1 knockout mice missing the BMAL1 protein only during adult life and compared them with conventional knockouts in which the gene is absent during development.

In both cases, the clock was paralyzed. Cyclical variation in gene expression, behavior, and blood pressure was abolished. However, while some effects suggestive of aging were common to both strains of mice - cataracts and signs of neurodegeneration - others, including lifespan, fertility, and signs of arthritis were absent when Bmal1 deletion was delayed until after birth. Indeed, in some cases - such as the capacity for hair regrowth after shaving - the impact of the knockout was reversed.

Analysis of gene expression showed that while both knockouts stopped genes oscillating in a circadian rhythm, the conventional knockouts also changed the overall expression of many non-cycling genes, which functionally may explain the divergent findings.

"Others have found that the Bmal1 gene, although expressed early, only begins to oscillate late in development, so many of the consequences of deleting the gene early may reflect off-target effects, unrelated to its role in the clock," said Guangrui Yang PhD, co-first author and a research assistant professor in Pharmacology. However, he added future studies aim to elucidate when and if Bmal1 begins to function as a clock gene in utero.

The conventional knock out of Bmal1 has been used extensively to implicate the molecular clock in body functions and disease. The findings prompt reconsideration of these assumptions and highlight the need to understand the role of clock genes during development.

"Indeed, the importance of Bmal1 expression during development in the determination of lifespan is reminiscent of the Barker hypothesis, which postulates that the fetal environment influences disease expression and lifespan in humans after birth," FitzGerald suggested. "The Barker hypothesis has been thought to reflect the epigenetic impact of maternal exposures, such as to cigarettes, alcohol, or toxins in the environment. Given the anticipatory role of the clock, an intriguing possibility raised by these findings is that the timing of such exposures might modulate their impact on postnatal life."


Other co-authors are Lihong Chen, Gregory R. Grant, Georgios Paschos, Wen-Liang Song, Erik S. Musiek, Vivian Lee, Sarah C. McLoughlin, Tilo Grosser, and George Cotsarelis. FitzGerald is also the director of the Institute for Translational Medicine and Therapeutics at Penn.

This research was supported by the National Heart, Lung and Blood Institute (HL097800) and the University of Pennsylvania Genomics Frontiers Institute's Translational and Personalized Genomics Centers Initiative.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania(founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $409 million awarded in the 2014 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2014, Penn Medicine provided $771 million to benefit our community.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.